AbbVie gets EU approval for expanded VENCLYXTO cancer drug combinations

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/22/2026

1. ACN
2. NVDA
3. SPCX
4. MSTR
5. MU
6. RGA
7. APGE
8. ABBV
9. DFTX
10. BAUFF

Go back to AbbVie gets EU approval for expanded VENCLYXTO cancer drug combinations
AbbVie (NYSE: ABBV) Delayed: 216.49 --0 (-0%)
Previous Close $216.49    52 Week High $68.12 
Open $216.49    52 Week Low $50.71 
Day High $216.49    P/E 46.96 
Day Low $216.49    EPS $4.61 
Volume 52,713